Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANAPTYSBIO, INC.

(ANAB)
  Report
Delayed Quote. Delayed Nasdaq - 01/25 04:00:00 pm
32.5 USD   +0.06%
01/05AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021AnaptysBio Files $300 Million Mixed Shelf
MT
2021INSIDER SELL : Anaptysbio
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ANAPTYSBIO, INC.
01/05AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021AnaptysBio Files $300 Million Mixed Shelf
MT
2021INSIDER SELL : Anaptysbio
MT
2021Anaptysbio announces appointment of daniel faga to board of directors
AQ
2021AnaptysBio Announces Appointment ofáDaniel Faga to Board of Directors
AQ
2021AnaptysBio, Inc. Announces Appointment of Daniel Faga to Board of Directors
CI
2021AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference
GL
2021AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference
GL
2021ANAPTYSBIO : Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data - Form ..
PU
2021AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
AQ
2021AnaptysBio, Inc. Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
CI
2021Wedbush Adjusts Price Target for AnaptysBio to $35 From $32, Maintains Neutral Rating
MT
2021AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates..
PU
2021AnaptysBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended S..
CI
2021AnaptysBio Announces Third Quarter 2021 Financial Results andáProvides Pipeline Updates
AQ
More most relevant news
All news about ANAPTYSBIO, INC.
01/05AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021AnaptysBio Files $300 Million Mixed Shelf
MT
2021INSIDER SELL : Anaptysbio
MT
2021Hexima Names New Chief Development Officer
MT
2021ANAPTYSBIO, INC : Completion of Acquisition or Disposition of Assets (form 8-K)
AQ
2021Anaptysbio announces appointment of daniel faga to board of directors
AQ
2021ANAPTYSBIO, INC : Change in Directors or Principal Officers (form 8-K)
AQ
2021AnaptysBio Announces Appointment ofáDaniel Faga to Board of Directors
AQ
2021AnaptysBio, Inc. Announces Appointment of Daniel Faga to Board of Directors
CI
2021AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference
GL
More news
News in other languages on ANAPTYSBIO, INC.
2021VENTE D'INITIÉS : Anaptysbio
2021AnaptysBio s'entend avec Sagard Healthcare pour monétiser une partie des redevances sur..
2021L'essai de mi-parcours d'AnaptysBio montre que le candidat-médicament Imsidolimab peut ..
2021MISE À JOUR SECTORIELLE : Les actions du secteur de la santé ont baissé mercredi
2021MISE À JOUR SECTORIELLE : Les actions du secteur de la santé sous-performent le marché mer..
2021MISE À JOUR : AnaptysBio obtient l'approbation accélérée de la FDA pour la deuxième indica..
2021AnaptysBio reçoit l'approbation accélérée de la FDA pour la deuxième indication du Jemp..
2021L'achat significatif d'actions AnaptysBio (ANAB) par des initiés prolonge la tendance à..
2021AnaptysBio (ANAB) fait l'objet d'un achat significatif de la part d'un initié, prolonge..
2021AnaptysBio obtient l'approbation conditionnelle de la Commission européenne pour le méd..
More news
Analyst Recommendations on ANAPTYSBIO, INC.
2021Wedbush Adjusts Price Target for AnaptysBio to $35 From $32, Maintains Neutral Rating
MT
2021Wedbush Lifts AnaptysBio's Price Target to $32 From $25 on Dostarlimab Royalty Agreemen..
MT
2021ANAPTYSBIO : Releases Data From Phase 2 GALLOP Trial For Imsidolimab Drug, Wedbush Says; K..
MT
2021ANAPTYSBIO : Wedbush Lifts AnaptysBio's Price Target to $25 From $20 on Dostarlimab Update..
MT
2021ANAPTYSBIO : HC Wainwright Initiates AnaptysBio at Buy Rating With $43 Price Target
MT
More recommendations
Press releases
01/05AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021ANAPTYSBIO, INC : Completion of Acquisition or Disposition of Assets (form 8-K)
AQ
2021Anaptysbio announces appointment of daniel faga to board of directors
AQ
2021ANAPTYSBIO, INC : Change in Directors or Principal Officers (form 8-K)
AQ
2021AnaptysBio Announces Appointment ofáDaniel Faga to Board of Directors
AQ
More press releases
Upcoming event on ANAPTYSBIO, INC.
03/07/22